Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.

Oncologist · 2025 · PMC12475964 · PMID 40891895

Europe PMC DOI

hedged sentences

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

borderline significantP = .057so close (0.05 < p ≤ 0.1)

A borderline significant benefit on PFS was observed for early interruption (HR = 0.61, P = .057), while late interruption (HR = 0.60, P = .183) and interruptions based on duration (≤2 cycles: HR = 0.46, P = .138; >2 cycles: HR = 0.67, P = .096) were not statistically significant.

also in 11,409 other papers

showed a trendno p-value reported

When stratified by timing of interruption, both early (HR = 0.56, 95% CI: 0.27-1.15, P = .113) and late interruptions (HR = 0.57, 95% CI: 0.29-1.09, P = .090) still showed a trend toward better PFS, though not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.